Global Cancer Vaccines Market Size, Share, Growth & Trends Analysis Report By Technology (mRNA-based Cancer Vaccines, Vector-based Cancer Vaccines, Dendritic Cell Cancer Vaccines, Tumor Antigen Cancer Vaccines) By Type of Cancer (Breast Cancer, Prostate Cancer, Lung Cancer, Cervical Cancer, Colorectal Cancer, Other Cancer Types) By Type of Vaccine (Preventive (Prophylactic) Vaccines, Therapeutic (Treatment) Vaccines) By End-User (Hospitals, Cancer Research Institutes, Clinics, Ambulatory Surgical Centers): Regional Outlook, Growth Potential and Segments Forecast 2024-2030


Summary of Report:

The Global Cancer Vaccines Market size was USD 9.69 billion in 2023 and it is expected to grow to USD 17.86 billion in 2031 with a CAGR of 10.55% in the 2024-2031 period. 


Original price was: $3,999.00.Current price is: $2,999.00.
Original price was: $4,999.00.Current price is: $3,999.00.
Original price was: $9,999.00.Current price is: $8,999.00.

Do You have any Budget constraints?
Simply Ask our Sales Team About it.



Global Cancer Vaccines Market: Overview

The global cancer vaccines market is the industry encompassing the development, production, and distribution of vaccines specifically designed for the prevention or treatment of cancer. This market is a dynamic and rapidly growing field within the broader healthcare landscape. Advancements in immunological research and vaccine technologies are leading to the development of more targeted and effective cancer vaccines. This includes personalized vaccines tailored to individual patients, as well as novel delivery methods and therapeutic approaches.

There is a growing emphasis on preventive healthcare and early intervention strategies in cancer management. This trend favours the adoption of cancer vaccines, particularly those with prophylactic capabilities. The global incidence and mortality rates of cancer are steadily increasing, creating a pressing need for effective preventive and therapeutic strategies. Cancer vaccines offer a promising avenue to address this growing public health challenge.

Global Cancer Vaccines Market: Covid-19 Impact

The global focus on COVID-19 vaccines has potentially increased public awareness and acceptance of vaccination in general, which could benefit the adoption of cancer vaccines in the future. The pandemic has spurred rapid advancements in vaccine development and manufacturing technologies, which could benefit the development of new cancer vaccines. The increased use of telehealth during the pandemic may improve access to cancer care and facilitate patient participation in clinical trials for cancer vaccines.

Many cancer vaccine clinical trials were delayed or halted due to the pandemic, hindering research and development progress. The focus on COVID-19 response diverted resources and attention away from other healthcare priorities, including cancer research and treatment. Fear of COVID-19 exposure and disruptions to healthcare services led to a decline in cancer screenings and diagnoses, potentially delaying cancer detection and treatment.

Overall, the COVID-19 pandemic has had a mixed impact on the global cancer vaccines market. While it has presented challenges, it has also highlighted the importance of cancer research and vaccine development and potentially paved the way for future advancements in the field.

Global Cancer Vaccines Market: Growth Drivers

1. Rising Cancer Incidence:

The global prevalence of cancer continues to rise, driving the need for effective treatments. Cancer vaccines offer a promising avenue for prevention and treatment, contributing to the growing demand for such therapies.

2. Advancements in Immunotherapy: 

Immunotherapy, including cancer vaccines, has witnessed significant advancements. The success of immune checkpoint inhibitors and CAR-T cell therapies has spurred interest in developing vaccines that harness the body’s immune system to target and eliminate cancer cells.

3. Focus on Personalized Medicine::

The trend towards personalized medicine emphasizes the development of targeted therapies tailored to individual patients. Cancer vaccines, especially those designed to target specific tumor antigens, align with the principles of personalized medicine.

Global Cancer Vaccines Market: Restraining factors

1. Complexity of Cancer Immunology:

Understanding the complex interactions between cancer cells and the immune system poses challenges. The intricate nature of cancer immunology makes it difficult to design vaccines that consistently produce strong and durable anti-cancer responses.

2. Limited Efficacy in Some Cancers:

The effectiveness of cancer vaccines can vary among different types of cancers. Some tumors may not respond well to immunotherapy, including vaccines, leading to limitations in the scope of application for certain cancer types.

Global Cancer Vaccines Market:  Opportunity factors

1. Expanding Indications and Targets:

Identifying new tumor antigens and expanding the range of cancer types that can be targeted by vaccines present opportunities for market growth. Research efforts focusing on a broader spectrum of cancers could lead to the development of more effective vaccines.

2. Combination Therapies with Other Immunotherapies:

Exploring combination therapies involving cancer vaccines and other immunotherapies, such as immune checkpoint inhibitors, may enhance treatment outcomes. Synergistic effects could lead to improved efficacy and a broader application in different cancer types.

Global Cancer Vaccines Market: Challenges

1. Tumor Heterogeneity: 

Tumor heterogeneity, where cancer cells within a single tumor may have different genetic profiles, poses a challenge. Developing vaccines that effectively target this heterogeneity and address the diversity of cancer cells is a complex task.

2. Immune Suppression in the Tumor Microenvironment:

The tumor microenvironment can create an immunosuppressive environment, hindering the immune response generated by cancer vaccines. Overcoming the immunosuppressive nature of tumors is a significant challenge in developing effective vaccines.

Global Cancer Vaccines Market: Segmentation

  • Based On Type of Cancer: The market is segmented into Breast Cancer, Prostate Cancer, Lung Cancer, Cervical Cancer, Colorectal Cancer and Others. Among these the Cervical cancer is the leading cause of cancer death worldwide, with millions of new cases diagnosed each year.  
  • Based On Technology: The market is segmented into mRNA-based Cancer Vaccines, Vector-based Cancer Vaccines, Dendritic Cell Cancer Vaccines and Tumor Antigen Cancer Vaccines. Among these Tumor antigen cancer vaccines currently hold the majority of the revenue share. 
  • Based On Type of Vaccine: Based on Type of Vaccine segmentation, the market is further divided into Preventive (Prophylactic) Vaccines and Therapeutic (Treatment) Vaccines. Among these, the Preventive (Prophylactic) Vaccines contributes largest revenue share.
  • Based On End-User: Based on End-User segmentation, the market is further divided into Hospitals, Ambulatory Surgical Centers (ASCs), and Clinics. Among these, the Hospitals contributes largest revenue share.
  • Based On Region: Based on Region, the market is segmented into five key geographical regions namely – North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Global Cancer Vaccines Market: Regional Insights

1. North America

North America currently holds the largest market share due to factors like high healthcare spending and extensive vaccination programs favor cancer vaccine adoption. Significant prevalence of various cancers, particularly breast, lung, and prostate, creates a large market demand. Leading pharmaceutical companies and research institutions drive innovation in the field.

2. Europe

Europe follows North America in market size, driven by factors like strong public healthcare infrastructure and government initiatives promoting vaccine access. Growing emphasis on personalized cancer treatments creates opportunities for tailored vaccines. Rising cancer incidence among the aging population fuels market growth.

3. Asia-Pacific

Asia Pacific demonstrates the highest growth potential due to a vast and rapidly growing populations with increasing cancer rates offer significant market potential. Increasing disposable income and investments in healthcare infrastructure improve access to vaccines. Countries like China and India are witnessing rapid advancements in cancer research and vaccine development.

4. Latin America

Latin America holds significant potential for market growth, public and private healthcare investments are improving access to cancer treatment and preventive measures. Growing awareness about cancer and its prevention is leading to increased demand for vaccines. Some countries are implementing national vaccination programs, particularly for HPV vaccines.

5. Middle East and Africa

The MEA region currently holds the smallest market share, but it is expected to see modest growth in the coming years. Increasing cancer incidence rates, particularly in certain regions, create market demand. Growing urban populations and lifestyle changes are associated with higher cancer risks. Investments in healthcare infrastructure are slowly improving access to cancer treatment and prevention options.

Global Cancer Vaccines Market: Competitive Landscape

  • Vaccinogen, Inc.,
  • GlaxoSmithKline plc (GSK),
  • Merck & Co., Inc.,
  • Advaxis Inc.,
  • Amgen Inc.,
  • Immunocellular Therapeutics, Ltd,
  • Generex Biotechnology Corporation,
  • Dynavax Technologies Corporation,
  • F Hoffmann-La Roche AG,
  • Moderna Inc.

Global Cancer Vaccines Market: Recent Developments

  • F Hoffmann-La Roche AG: In December 2023, Roche partners with ElevateBio to develop and commercialize novel T-cell receptor (TCR) therapies for cancer treatment.
  • Generex Biotechnology Corporation: In July 2023, Announced a definitive agreement to acquire NuGenerex Immuno-Oncology, Inc., a clinical-stage biotechnology company developing a Ii-Key T cell vaccine platform for cancer and infectious diseases.

Table of Content

2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2. Breakdown of Primary Respondents
3.5. Forecasting Modality
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5.1. Value Chain Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis
6.1. Overview
6.2. mRNA-based Cancer Vaccines
6.3. Vector-based Cancer Vaccines
6.4. Dendritic Cell Cancer Vaccines
6.5. Tumor Antigen Cancer Vaccines
7.1. Overview
7.2. Breast Cancer
7.3. Prostate Cancer
7.4. Lung Cancer
7.5. Cervical Cancer
7.6. Colorectal Cancer
7.7. Other Cancer Types
8.1. Overview
8.2. Preventive (Prophylactic) Vaccines
8.3. Therapeutic (Treatment) Vaccines
9.1. Overview
9.2. Hospitals
9.3. Cancer Research Institutes
9.4. Clinics
9.5. Ambulatory Surgical Centers
10.1. Overview
10.2. North America
10.2.1. U.S.
10.2.2. Canada
10.3. Europe
10.3.1. Germany
10.3.2. France
10.3.3. U.K
10.3.4. Italy
10.3.5. Spain
10.3.6. Rest of Europe
10.4. Asia-Pacific
10.4.1. China
10.4.2. India
10.4.3. Japan
10.4.4. South Korea
10.4.5. Australia
10.4.6. Rest of Asia-Pacific
10.5. Rest of the World
10.5.1. Middle East
10.5.2. Africa
10.5.3. Latin America
11.1. Overview
11.2. Competitive Analysis
11.3. Market Share Analysis
11.4. Major Growth Strategy in the Global Cancer Vaccines Market,
11.5. Competitive Benchmarking
11.6. Leading Players in Terms of Number of Developments in the Global Cancer Vaccines Market,
11.7. Key developments and Growth Strategies
11.7.1. New Product/End-Use Deployment
11.7.2. Merger & Acquisitions
11.7.3. Joint Ventures
11.8. Major Players Financial Matrix
11.8.1. Sales & Operating Income, 2022
11.8.2. Major Players R&D Expenditure. 2022
12.1. Vaccinogen, Inc.
12.1.1. Company Overview
12.1.2. Financial Overview
12.1.3. Products Offered
12.1.4. Key Developments
12.1.5. SWOT Analysis
12.1.6. Key Strategies
12.2. GlaxoSmithKline PLC (GSK)
12.2.1. Company Overview
12.2.2. Financial Overview
12.2.3. Products Offered
12.2.4. Key Developments
12.2.5. SWOT Analysis
12.2.6. Key Strategies
12.3. Merck & Co., Inc.
12.3.1. Company Overview
12.3.2. Financial Overview
12.3.3. Products Offered
12.3.4. Key Developments
12.3.5. SWOT Analysis
12.3.6. Key Strategies
12.4. Advaxis Inc.
12.4.1. Company Overview
12.4.2. Financial Overview
12.4.3. Products Offered
12.4.4. Key Developments
12.4.5. SWOT Analysis
12.4.6. Key Strategies
12.5. Amgen Inc.
12.5.1. Company Overview
12.5.2. Financial Overview
12.5.3. Products Offered
12.5.4. Key Developments
12.5.5. SWOT Analysis
12.5.6. Key Strategies
12.6. Immunocellular Therapeutics, Ltd
12.6.1. Company Overview
12.6.2. Financial Overview
12.6.3. Products Offered
12.6.4. Key Developments
12.6.5. SWOT Analysis
12.6.6. Key Strategies
12.7. Generex Biotechnology Corporation
12.7.1. Company Overview
12.7.2. Financial Overview
12.7.3. Products Offered
12.7.4. Key Developments
12.7.5. SWOT Analysis
12.7.6. Key Strategies
12.8. Dynavax Technologies Corporation
12.8.1. Company Overview
12.8.2. Financial Overview
12.8.3. Products Offered
12.8.4. Key Developments
12.8.5. SWOT Analysis
12.8.6. Key Strategies
12.9. F Hoffmann-La Roche AG
12.9.1. Company Overview
12.9.2. Financial Overview
12.9.3. Products Offered
12.9.4. Key Developments
12.9.5. SWOT Analysis
12.9.6. Key Strategies
12.10. Moderna Inc.
12.10.1. Company Overview
12.10.2. Financial Overview
12.10.3. Products Offered
12.10.4. Key Developments
12.10.5. SWOT Analysis
12.10.6. Key Strategies


Frequently Asked Questions

  • Which is the leading segment in the Global Cancer Vaccines Market?

    Among End-Users, Hospitals dominate the market share. This is because Hospitals cater to a wider range of medical specialties and attract a significantly higher volume of patients.
  • What are the key factors driving the Global Cancer Vaccines Market?

    Increasing Awareness and Education, Focus on Personalized Medicine, Advancements in Immunotherapy, Government Initiatives and Funding and Rising Cancer Incidence are the major factors driving the market growth.
  • Which region will contribute notably towards the Global Cancer Vaccines Market?

    North America region to contribute the major share towards the market growth.
  • What are the key players in Global Cancer Vaccines Market?

    Vaccinogen, Inc., GlaxoSmithKline plc (GSK), Merck & Co., Inc., Advaxis Inc., Amgen Inc., Immunocellular Therapeutics, Ltd, Generex Biotechnology Corporation, Dynavax Technologies Corporation, F Hoffmann-La Roche AG, Moderna Inc.